^
Association details:
Biomarker:KIAA1549-BRAF fusion
Cancer:Astrocytoma
Drug:Koselugo (selumetinib) (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Excerpt:
...Plasma drug concentrations and pharmacokinetic parameters (Phase I)`Stratum-specific progression-free survival distribution (PFS) (phase II)`Presence or absence of BRAF V600E mutations or BRAF KIAA1549 fusion (phase II)`Progression-free survival (retreatment study)...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

AZD6244 in Children With Low-Grade Gliomas

Excerpt:
...- Stratum 1: Patients with progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and with a BRAF aberration i.e. BRAF (V600E) mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively. ...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Selumetinib in Children with BRAF-Aberrant or Neurofibromatosis type 1-Associated Recurrent, Refractory or Progressive Low-Grade Glioma: a Multi-Center Phase II Trial

Excerpt:
...Stratum 1 included...pilocytic astrocytoma (PA) harboring either one of the two most common BRAF aberrations (KIAA1549-BRAF fusion or the BRAFV600E mutation)...On stratum 1, 9/25 (36%) patients achieved a partial response (PR)...Among the tumors with a KIAA1549-BRAF fusion, 7/18 (38.9%) had a PR...
DOI:
10.1016%2FS1470-2045(19)30277-3
Trial ID: